Director, MSL Operations
Karen Serafini brings a broad range of experience in the pharmaceutical, healthcare, and medical device industries to TriNet Pharma.
She began her pharmaceutical career in clinical development at Covance and then ICON, leading the startup of the ICON Nashville office. Karen’s first MSL role was at Fujisawa (now Astellas) as a Transplant/Immunology MSL, focusing on solid organ transplantation. Utilizing her transplant experience, Karen worked with CTI Clinical Trial and Consulting Services in the Clinical Development, Business Development and Client Services Divisions until accepting a position at Tennessee Oncology as the Administrator for a new BMT/Hematologic Malignancy Program. Karen led the program through its initial growth years, achieving FACT accreditation within 3 years. Karen returned to industry in 2010, leading a successful BLA submission and approval at BTG for Voraxaze®, a high-dose methotrexate toxicity antidote. Joining the newly launched Field Medical team at BTG as an MSL, Karen and her team focused on interventional oncology therapies, specifically in GI/liver cancers. Karen held roles as a Senior MSL and
MSL Manager through the acquisition of BTG by Boston Scientific in 2019.
Karen will focus on developing new business for TriNet Pharma. She will also play a key role in leading many of TriNet Pharma’s global contract MSL teams.
Karen holds a Bachelor of Science degree from Middle Tennessee State University, with double majors in Chemistry and Biology.
Karen and her music producer husband enjoy living in Nashville, TN with its incredible music venues, artists, and restaurants.